The recent safety update to Rinvoq’s label is having the anticipated impact, AbbVie Inc.execs said during the firm’s fourth quarter and full year 2021 earnings call on 2 February, and the Janus kinase inhibitor is likely to return to growth in its lead indication of rheumatoid arthritis during the second quarter of 2022. Rinvoq, along with the IL-23 blocker Skyrizi, is a key cog in AbbVie’s strategy for enduring sales erosion of its top-seller Humira when US biosimilars of adalimumab begin entering the market in 2023.
A primary area of inquiry on the investor call was how Rinvoq (upadacitinib) has fared since the US Food and Drug Administration added a black box warning to labeling reflecting safety concerns across the entire JAK class; the change limited the class to second-line therapy behind anti-TNF drugs, such as Humira. (Also see "FDA Warnings And Restrictions On JAKs Curb Growth Potential Of Big Brands" - Scrip, 1 September, 2021
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?